Kirkland Advises Crown Laboratories on $924M Acquisition of Revance
August 13, 2024
August 13, 2024
CHICAGO, Illinois, Aug. 13 -- Kirkland and Ellis, a law firm, issued the following news release:
Kirkland & Ellis advised Crown Laboratories, Inc., a privately held, global innovative leader in the skincare industry, on a definitive merger agreement to purchase Revance Therapeutics, Inc. (NASDAQ: RVNC), a biotechnology company aimed at setting the new standard in healthcare with innovative aesthetic and therapeutic offerings.
The acquisition was announced August 12, . . .
Kirkland & Ellis advised Crown Laboratories, Inc., a privately held, global innovative leader in the skincare industry, on a definitive merger agreement to purchase Revance Therapeutics, Inc. (NASDAQ: RVNC), a biotechnology company aimed at setting the new standard in healthcare with innovative aesthetic and therapeutic offerings.
The acquisition was announced August 12, . . .